| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $56.4M | — | +99.0% |
| R&D Expense | $46.7M | — | +30.2% |
| SG&A Expense | $13.3M | — | +13.1% |
| Operating Income | -$3.6M | — | +81.1% |
| Pre-tax Income | $2.3M | — | +119.6% |
| Income Tax | -$1.5M | — | — |
| Net Income | $3.8M | — | +132.5% |
| EPS (Basic) | $0.06 | — | +131.6% |
| EPS (Diluted) | $0.05 | — | +126.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $193.7M | +50.9% | +38.7% |
| Short-term Investments | $354.1M | -19.3% | -18.5% |
| Current Assets | $613.5M | +6.2% | +1.3% |
| Total Assets | $697.5M | +4.4% | -6.0% |
| Current Liabilities | $34.5M | -24.0% | -1.6% |
| Total Liabilities | $42.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$48.9M | — | -139.0% |
| Capital Expenditures | $215K | — | -60.6% |
| Investing Cash Flow | $90.9M | — | +196.3% |
| Financing Cash Flow | $23.4M | — | +104.3% |
| Free Cash Flow | -$49.2M | — | -139.4% |
| -20.9% |
| Stockholders' Equity | $655.5M | +6.6% | -4.9% |